Home | Welcome to Contract Pharma   
Last Updated Sunday, December 21 2014

Print

Macrocyclics, Roche in Nuclear Medicine Pact



Published May 24, 2013
Related Searches: Development
Macrocyclics has entered a new collaborative research agreement with Roche for the continued development of novel chelating agents designed by Macrocyclics for Roche's applications. The collaboration aims to speed up the clinical development process. The new project will build on established progress related to lead-212 (212Pb) and novel chelate architecture for radioimmunotherapy. 
 
"We are privileged to be working with the world leader in oncology and antibody technology and are excited to contribute in the development of powerful new therapies based on lead-212," said Garry Kiefer, chief executive officer of Macrocyclics.


blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On